In this study, we constructed, validated, and evaluated a signature composed of GCLM, IPCEF1, MsrA, and SBNO2, which effectively predicted the prognosis and was involved in immune-related pathways in patients with ccRCC. The gene discussed is GCLM; the disease is nonpapillary renal cell carcinoma.